Stem cell pioneer sets sights on Japan – Japan Times features Neil Riordan, PhD of Medistem Panama

"We enjoy the advantage of having a large amount of clinical data on 2,000 patients. So we analyzed who received which cells and which cells worked best in different conditions. This allowed us to create our selection process through molecular profiling,” explained Medistem (Panama) Founder and CEO Dr. Neil Riordan. Operating what is arguably the [...]

Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board

Panama City, Panama (PRWEB) January 14, 2014 Translational Biosciences, a subsidiary of Medistem Panama has received the county’s first clinical trial approval for the treatment of rheumatoid arthritis with human umbilical cord-derived mesenchymal stem cells (MSC) from the Comité Nacional de Bioética de la Investigación Institutional Review Board (IRB). Rheumatoid Arthritis (RA) is an autoimmune [...]

Medistem Panama Awarded ISO 9001 International Global Certification

Awarded this: CERTIFICATION for the Quality Management System of: MEDISTEM PANAMA Offices included in the scope: Ciudad del Saber, Edificio # 221, piso # 2, Clayton, Ancón Panama City, Republic of Panama The scope includes the following activities: Isolation of stem cells from adipose tissue(ADSC) and mononuclear cells from bone marrow. Expansion and harvest of [...]

Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic

Leo Bockeria, Vladimir Bogin, Olga Bockeria, Tatyana Le, Bagrat Alekyan, Erik J Woods, Amalia A Brown, Thomas E Ichim and Amit N Patel Journal of Translational Medicine 2013, 11:56 doi:10.1186/1479-5876-11-56 Published: 5 March 2013 Heart failure is one of the key causes of morbidity and mortality world-wide. The recent findings that regeneration is possible in [...]

Medistem Inc. Annual Letter to Shareholders

SAN DIEGO, CA--(Marketwire - Jan 4, 2013) - Medistem Inc. ( PINKSHEETS : MEDS ) today issues the following letter to shareholders. Dear Fellow Shareholders, 2012 was marked by significant progress in the development of the Endometrial Regenerative Cell (ERC), our new universal donor "stem cell drug." Most significantly, we initiated a double blind, placebo [...]

2013-01-14T17:14:08+00:00January 14th, 2013|medistem, News, Stem Cell Research|

Medistem Advances Type 1 Diabetes Stem Cell Technology Licensed From Yale

SAN DIEGO, CA -- (Marketwire) -- 09/12/12 -- Medistem Inc. (PINKSHEETS: MEDS) announced today completion of the first phase of a joint project with the Shumakov Research Center of Transplantology and Artificial Organs of the Russian Federation and its Russian and CIS licensee ERCell. The collaboration is based on using Endometrial Regenerative Cell (ERC) technology [...]

2012-09-13T17:37:45+00:00September 13th, 2012|Diabetes, News, Stem Cell Research|

Endometrial Stem Cells Yeild Postive Clinical Trial Results for Heart Disease

More progress reported on the treatment of heart disease with endometrial stem cells. Neil Riordan, PhD is one of the early pioneers of endometrial stem cell technology. Dr. Riordan is also the Founder and President of the Stem Cell Institute in Panama City, Panama. Positive Two-Month Data From RECOVER-ERC Congestive Heart Failure Trial SAN DIEGO, [...]

2012-06-06T17:50:59+00:00June 6th, 2012|Adult Stem Cells, Heart Disease, News, Stem Cell Research|

Medistem Signs Exclusive Worldwide License With Yale University for Treatment of Type 1 Diabetes Using Stem Cells

Acquisition of Intellectual Property and Data Leads to Expansion of Medistem Therapeutic Pipeline SAN DIEGO, CA, Mar 07, 2012 (MARKETWIRE via COMTEX) -- Medistem Inc. (pinksheets:MEDS) and Yale University have signed an exclusive worldwide licensing agreement covering the generation of pancreatic islets from stem cells such as the Endometrial Regenerative Cell (ERC). These pancreatic islets [...]

2012-03-12T18:11:33+00:00March 12th, 2012|Adult Stem Cells, News, Stem Cell Research|